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Abstract. Background: Gemcitabine is first-line therapy for
advanced pancreatic ductal adenocarcinoma (PDAC) with a
poor survival and response rate. Hyperbaric oxygenation
(HBO) enhances delivery of oxygen to hypoxic tumor cells
and increases their susceptibility to cytotoxic effects of
chemotherapy. We hypothesized that the anticancer activity
of gemcitabine (GEM) may be enhanced if tumor cells are
placed in an oxygen-rich environment. The present study
evaluated the effects of gemcitabine, HBO and their
combination on apoptosis of tumor cells. Materials and
Methods: PANC-1 and AsPc-1 PDAC tumor cell lines were
used. Cultured tumor cells were treated with GEM at its
growth-inhibitory concentration (IC50) and HBO at 2.5 ATA
for 90 min or a combination of both (HBO then GEM and
GEM then HBO). Twenty-four hours later, apoptotic cells in
each group were analyzed and the apoptotic index (AI) was
calculated. Results: PANC-1 cell line: HBO alone had no
effect on AI: 6.5±0.1 vs. 5.9±0.1. HBO before and after
gemcitabine did not further increase AI: 8.2±0.1 (HBO-
GEM), 8.5±0.1 (GEM-HBO) vs. 8.1±0.1 (GEM). The
combination of HBO and gemcitabine significantly increased
AI: 10.7±0.02 (p<0.001 vs. all groups). AsPc-1 cell line:
HBO-alone had no effect on AI: 5.9±0.1 vs. 5.9±0.1. HBO
before and after gemcitabine did not further increase AI:
8.2±0.1 (HBO-GEM), 8.4±0.1 (GEM-HBO) vs. 8.0±0.1
(GEM). The combination of HBO and gemcitabine
significantly increased AI: 9.7±0.1 (p<0.001 vs. all groups).
Conclusion: HBO-alone, whether administered before and
after gemcitabine has no effect on apoptosis of PDAC cells
in vitro. HBO significantly enhanced gemcitabine-induced
apoptosis when administered during gemcitabine. Our
findings suggest that the time window would be critical for
using HBO as adjuvant to chemotherapy. 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive human malignancies and the fourth leading cause
of cancer-related death in the United States (1). Systemic
chemotherapy, radiotherapy or a combination of both have
been utilized following surgery in order to improve outcome.
However, there has been no significant improvement in the
median survival time (less than six months) and 5-year
survival rate (3%-5%) despite clinical and research efforts
(2). Although adjuvant and neoadjuvant therapy has been
widely used in recent years, the best choice for treatment
modality remains highly controversial (3). 
The searching for new adjuvant treatments targets
characteristic properties of the cells. Hypoxia is a common
feature of solid tumors. They usually grow so rapidly to
exceed their blood supply, leaving portions of the tumor with
regions where oxygen availability is considerably limited.
Tumor hypoxia is also due to a high degree of cell
proliferation which causes higher cell density and thus
depletes local oxygen. Hypoxic tumor cells are usually
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resistant to radiotherapy and chemotherapy because oxygen
is essential for the cytotoxic activity of these therapies.
Nevertheless, hypoxic tumors can be made more susceptible
to treatment by increasing the amount of oxygen inside (4). 
Hyperbaric oxygen therapy (HBO) is one of the modalities
to temporarily alleviate or eliminate hypoxic status in growing
tumor cells. By providing 100% oxygen at elevated
atmospheric pressure, HBO increases the partial pressure of the
oxygen gas and thus forces more oxygen to be dissolved in the
plasma, which allows the extra oxygen to be diffused or
transported to the body tissues. HBO has been documented by
The Undersea and Hyperbaric Medicine Society to be
beneficial in 13 different diseases (5). The effects of HBO used
as adjuvant to radiotherapy or chemotherapy has been reviewed
(6). In vitro studies have demonstrated the beneficial effects of
HBO used adjuvant to chemotherapy in the treatment of
osteosarcoma, nasopharyngeal carcinoma CNE-2Z cells, and
murine model of PC-3 prostate cancer cell line and glioma
U251 cell lines (7-10). The use of HBO as adjuvant therapy for
pancreatic tumors has not been reported. Gemcitabine is a
pyrimidine anti-metabolite that with good clinical activity in
pancreatic, breast, ovarian, non-small-cell lung, and bladder
tumors (11). Gemcitabine is a first-line therapy for locally
advanced pancreatic cancer; however, severe resistance is
responsible for a response rate less than 20% and median
survival less than six months of (2). Although efforts to
overcome gemcitabine resistance have been made, the only
combination treatment that has shown a small but statistically
significant effect was gemcitabine with erlotinib, an epidermal
growth factor receptor inhibitor (12). We hypothesized that a
combination of HBO and gemcitabine may significantly
enhance the efficacy of gemcitabine for pancreatic tumors.
PANC 1 is an epithelioid carcinoma cell line derived from
human pancreas and AsPc-1 is a human pancreatic
adenocarcinoma cell line (13, 14). Both cell lines are relatively
sensitive to gemcitabine in vitro (15). These two cell lines were
used in the present study to investigate for the efficacy of
gemcitabine-alone, HBO-alone and the combination of both on
the apoptotic index (AI) in these two cell lines. 
Materials and Methods
Cell cultures. PANC-1 cell line and AsPc-1 cell line were used in the
present study. Tumor cells were derived from pancreatectomy samples
from patients with infiltrating ductal and intra-ductal carcinoma. Cells
from these two lines were cultured in Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich, Laborchemikalien, Seelze, Germany) with
10% fetal calf serum and a mixture of 100 IU/ml penicillin and 100
μg/ml streptomycin (all from GIBCO, Grand Island, NY, USA).
Hyperbaric chamber. A hyperbaric chamber, model Costruzioni
Riunite Moro; Quinto di Treviso, Italy, located in Padova’s ATIP
center was used for HBO therapy. The tumor cells were treated at
2.5 atmosphere absolute (ATA) and 100% oxygen for 90 min, with
five minutes for compression and five minutes for decompression.
Chemotherapy. Gemcitabine (Sigma-Aldrich Laborchemikalien) was
dissolved in Phosphate buffered saline (PBS) and used its 50%
growth-inhibitory concentration (IC50) for cultured tumor cells. Its
IC50 value for PANC-1 cell is 3.25×10–8 ng/ml and for AsPc-1 cell
is 1.27×10–7 ng/ml (16). 
Sample analysis. Apoptosis was measured quantitatively with the
use of the TUNEL assay. The ApopTag In situ Apoptosis Detection
kit (Chemicon, Temecula, CA, USA) was used according to the
manufacturer’s instructions. A cell was considered TUNEL-positive
if it was stained brown (from light to dark) and if it exhibited
apoptotic bodies, chromatin condensation and membrane blebbing.
The total number of TUNEL-positive tumor cells were counted in
five different high-power fields with a microscope (Nikon Eclipse
80i, magnification ×20, NIKON INSTRUMENTS INC, Melville,
NY, USA) and the average was calculated.
The total number of cells (both TUNEL-negative and -positive)
was also counted and the apoptosis index was calculated.
Treatment. Tumor cells from the PANC-1 cell line and the AsPc-1 cell
lines were prepared by seeding them in 35 mm Petri dishes at a
density of 4000 cells/cm2 72 h before the beginning of the treatment.
The tumor cells were divided into the following treatment groups.
GEM. The tumor cells were treated with gemcitabine alone at the
IC50 value. After 24 h, the culture media were replaced. The culture
media were replaced again after 24 h and after a further 48 hours,
the apoptotic index was analyzed with a TUNEL test. 
HBO. The tumor cells were treated with a quantity of PBS (as placebo)
equal to that used for dissolving gemcitabine for administering to the
experimental samples. After 24 h, the culture media were replaced and
the tumor cells were treated with HBO alone for 90 min at 2.5 ATA.
The culture media were replaced again after 24 h and after a further 48
h, the apoptotic index was analyzed with a TUNEL test. 
Control. The tumor cells were treated with PBS (as placebo) equal
in quantity to that used to dissolve gemcitabine for administering to
the experimental samples. After 24 h, the culture media were
replaced. The culture media were replaced again after 24 h and after
another 48 h the AI was analyzed with a TUNEL test. 
GEM-HBO. Gemcitabine, at the IC50 value for the tumor cells was
administered the tumor cells cultured for 24 h. The drug was then
eliminated by replacing the culture media. The tumor cells were
then treated with HBO at 2.5 ATA for 90 min. The culture media
were replaced 24 h later. The apoptotic index was analyzed with a
TUNEL test after 48 h. The AI was calculated as: AI=total number
of apoptotic cells counted/ total number of live cells counted. 
HBO-GEM. The tumor cells were first treated with HBO at 2.5 ATA
for 90 min. After 24 h, the culture media were replaced and the
tumor cells were treated with gemcitabine at the IC50 value. After 24
h, the culture media were replaced again and after another 48 h, the
AI was analyzed with a TUNEL test. 
GEM+HBO. Gemcitabine at the IC50 value for the tumor cells was
administered and HBO was administered for 90 min at 2.5 ATA at
the same time. After 24 h, the culture media were replaced and after
a further 48 h, the apoptotic index was analyzed with a TUNEL test. 
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Each treatment was repeated three times and for each sample, the
cells in 23 randomly selected fields of 0.157 mm2 within a 5 cm2
area were counted for apoptotic and living cells. During the
measuring of apoptotic cells, the number of all tumor cells in each
group was counted to determine the tumor cell growth under
different treatments.
Statistical analysis. Results are presented as the mean±SD. Multiple
comparisons among groups were analyzed by one-way analysis of
variance followed by the Tukey–Kramer method for post-hoc
analysis after confirmation of normal distribution of the data. Tukey
95% simultaneous confidence intervals were applied, or p-value
<0.05, when equality assumptions were rejected simultaneously. The
individual confidence level was 99.54%, or with p-value <0.0046.
Results
The apoptotic indices are summarized in Table I. HBO per
se had no significant effect on the induction of apoptosis in
either cell line. HBO when administered before or after
gemcitabine administration also had no significant effect on
gemcitabine-induced apoptosis in either tumor cell line.
HBO enhanced gemcitabine-induced apoptosis in both tumor
cell lines only when administered concurrently with
gemcitabine. 
There was no significant change in the total number of
tumor cells with therapy using HBO-alone or the control
group (data not shown).
Discussion
The main findings of the present study are that: i) HBO-
alone had no significant effect on inducing tumor cell
apoptosis; ii) gemcitabine-alone significantly increased
apoptosis of tumor cells; iii) administration of HBO before
or after gemcitabine treatment did not further increase
apoptosis; and iiii) administration of HBO concurrently with
gemcitabine treatment significantly enhanced gemcitabine-
induced apoptosis of the tumor cells. The AI was used to
evaluate antitumor activity of Cox inhibitor in a canine
model of human invasive urinary bladder cancer (21). The
AI was used in the present study to evaluate the efficacy of
HBO, gemcitabine and their combination in the induction of
apoptosis of pancreatic tumor cells. 
Solid tumors survive and proliferate in a hypoxic
environment. These slowly-proliferating hypoxic tumor cells
are less susceptible to chemotherapy and radiotherapy
because molecular oxygen and reactive oxygen species
(ROS) are essential for such therapies (6). Therapeutic
efficacy may be improved if the hypoxic state of the tumor
cells is eliminated. HBO is one of the modalities to
significantly increase oxygen availability around tumor cells
and thus has been evaluated as adjuvant to radiotherapy and
chemotherapy (6). It has been a concern that HBO induces
re-oxygenation of hypoxic tumor cells and an increase of
angiogenesis may potentially promote tumor cell growth and
recurrence of malignancy (6). Comprehensive investigations
are mandatory before HBO can be safely used in clinical
cancer therapy. 
Tang et al. investigated the effect of HBO on tumor
growth in an in vivo murine model of indolent prostate
cancer (9). Mice with induced tumors were randomized to
undergo 20 sessions of either therapy with HBO or air, under
standardized conditions and were observed for 4 weeks
before histological assessments of any palpable tumors that
had developed. It was found that exposure to HBO had no
effect on prostate cancer volume, tumor microvessel density,
proliferative index, and apoptosis markers in comparison to
the non-HBO group. Their study showed that HBO had no
tumor-stimulatory effect on prostate cancer. They suggested
that HBO may potentially be used safely in conjunction with
other therapeutic modalities (9). Lu et al. also reported that
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Table I. Effect of hyperbaric oxygen (HBO) treatment and gemcitabine (GEM) on apoptosis of PANC-1 and AsPc-1 pancreatic ductal
adenocarcinoma cells. Apoptotic indices are presented as mean±SD. HBO per se had no significant effect on apoptosis of tumor cells. Gemcitabine
significantly induced apoptosis of tumor cells. HBO significantly enhanced gemcitabine-induced apoptosis only when administered during
chemotherapy. Multiple comparisons among groups were analyzed as described in Materials and Methods. (The number of tumor cells for each
group were 4×103 cells/cm2 in Petri dish).
Treatment
Cell lines Control HBO GEM HBO-GEM GEM-HBO HBO+GEM
PANC-1 5.9±0.1 6.5±0.1 8.1±0.1* # 8.2±0.1* # 8.5±0.1* # 10.7±0.1** ## !! 
AsPc-1 5.9±0.1 5.9±0.1 8.0±0.1* # 8.2±0.1* # 8.4±0.1* # 9.7±0.1** ## !! 
Control: Without treatment; HBO: treated with HBO alone for 90 min at 2.5 ATA; GEM: treated with GEM alone; HBOT-GEM: treated with HBO
at 2.5 ATA for 90 min then after 24 h treated with GEM; GEM-HBOT: treated with GEM for 24 h then placed in drug-free culture media and treated
with HBO; GEM+HBOT: HBO was administered for 90 min at 2.5 ATA during therapy with GEM. *p<0.01 vs. control; #p<0.01 vs. HBOT; !!p<0.01
vs. GEM, HBOT-GEM and GEM-HBOT.
HBO inhibited proliferation in glioma U251 cells in vitro
(10). The natural doubling time for the tumor cells used in
the present study was approximately 52 h. The proliferation
of tumor cells was not examined in the present study because
treatment caused changes that may not be detectable 24 h
after treatment (9). Nevertheless, we did record tumor cell
numbers in the group treated with HBO-alone and control
group and found there was no significant difference in the
cell numbers in both groups, therefore ruling out a possible
stimulating effect of HBO on growth. As mentioned by
Schonmeyr et al., conflicting results on the effects of HBO
on tumors have been presented (22). Thus, some studies have
shown suppressed tumor growth and reduced metastatic rates
after HBO (23, 24); others have demonstrated enhanced
tumor progression or no effects at all (25, 26). Schonmeyr et
al. data showed that HBO does not accelerate squamous cell
proliferation or promote tumor growth. Furthermore, their
data showed that although HBO may decrease hypoxia
within the tumors, there is no evidence of HBO altering
angiogenesis or vascular invasion in squamous cancer cell
tumor deposits (22). Our study is in agreement with the
above findings that HBO has no tumor-stimulating effect in
the pancreatic tumor cell lines studied. 
Lu et al. reported that HBO-alone inhibited cell
proliferation and induced apoptosis of glioma U251 cells in
vitro (10). In our study, HBO-alone had no significant effect
on the AI for pancreatic tumor cells. It is known that HBO
increases the free oxygen radical level, which may cause
tumor cell damage. In their study, HBO was given three times
at 12 h intervals. Multiple HBO sessions may exceed the
tumor cells’ endogenous cellular antioxidant capacity, thus
creating oxidative stress leading to cell damage. Consistent
with the evidence that most chemotherapy agents cause tumor
cell death primarily by inducing apoptosis, resistance to
anticancer treatment is widely believed to involve mutations
that lead to de-regulated cellular proliferation and suppression
of mechanisms that control apoptosis. It has been observed
that tumors with exhibiting AI after one cycle of
chemotherapy are more likely to achieve pathological
regression. Increased apoptosis after chemotherapy may also
predict which patients will have a good pathological response
(27). The utility of HBO as adjuvant therapy in tumor
treatment is still under investigation. Bradfield et al. observed
four patients with head and neck cancer who apparently had
rapid progression of clinically-occult disease during or soon
after undergoing HBO (28). However, other studies have
reported on the beneficial effect of HBO as adjuvant therapy
in tumor treatment. Haffty et al. conducted a randomized
clinical trial to evaluate the role of HBO as adjuvant to
radiotherapy in the treatment of locally advanced squamous
cell carcinoma of the head and neck (29). The patients were
randomized to radiation-alone or radiation under HBO over
21 days to at total of 23 Gy. There was a highly significant
difference in complete clinical responses between the two
groups, with 21/25 complete clinical responses in the HBO
treated group compared with 13/25 complete clinical
responses in the control group, and a statistically insignificant
trend towards improved 5-year local control in the HBO
treated group (29% vs. 16%). There were no significant
differences between the two groups with respect to 5-year
survival, distant metastasis, or second primary tumors. They
concluded that the long-term outcomes from their randomized
trial demonstrated substantial improvements in response rate
after use of HBO. McDonald et al. conducted a study using
chemical carcinogen-induced squamous cell carcinoma in
Golden Syrian hamsters to determine the effects of HBO on
tumor management (30). Twenty hamsters underwent 30 HBO
seasons for 60 min each to 2.81 ATA, while 20 untreated
served as controls. At necropsy, animals receiving HBO had
significantly smaller tumors and had a trend toward fewer
cervical metastases. Ohgami et al. also demonstrated that HBO
enhanced anticancer activity of artemisinin in Molt-4 human
leukemia cells resulting in an additional 22% decrease in
growth (31). The present study shows that HBO, only when
simultaneously administered with gemcitabine significantly
increased apoptosis of pancreatic tumor cells in vitro. Time
may be an important factor to determine the efficacy of
therapeutic management. A recent clinical trial showed that
radiotherapy delivered immediately after HBO with
chemotherapy was safe, with virtually no late toxicities, and
seemed to be effective in patients with high-grade gliomas (32).
An in vitro study using highly metastatic murine osteosarcoma
cell lines found that HBO-alone significantly suppressed cell
proliferation, and HBO-plus carboplatin exhibited significant
synergism in suppression of cell proliferation. Authors also
reported that concomitant HBO clearly enhanced the
chemotherapeutic effects of carboplatin on both tumor growth
and lung metastasis in osteosarcoma-bearing mice (6). Further
study is needed to find an ideal HBO regime to maximize its
enhancing effect for chemotherapy and minimize its adverse
effect. In the present study, there was no effect on apoptosis if
HBO was administered either before or after chemotherapy.
Since our study was in vitro, the tumor cells were placed under
an oxygen-rich environment only when HBO was provided.
Enhanced antitumor activity of gemcitabine occurred only
when tumor cells were under hyperbaric hyperoxic condition.
Our study supports the notion that HBO may be useful as
adjuvant to chemotherapy in the management of cancer
treatment (5). Our study also suggests that the time window
may be critical for using HBO during chemotherapy. 
Although is still not fully-understood, multiple mechanisms
may be responsible for the enhancement of gemcitabine
induced apoptosis by HBO. HBO has been reported to directly
increase the uptake of 5-fluorouracil in dimetyl-α-
benzantracene-induced mammary tumors in vivo (33). It is
known that some chemotherapeutic drugs require oxygen to
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generate free oxygen radicals that in turn induce cytotoxicity.
HBO may disturb the membrane components of cells following
oxidation phenomena caused by ROS overproduction. A
change in the properties of any one membrane components is
anticipated to change the conductance of membrane-spanning
ion channels and thus cell function. HBO therefore may
facilitate drug access to the cell, if the drug is already close to
the cell. HBO may also slow down the elimination of the drug
due to inhibition of protein response, increase membrane
thickness, or oxidation of the amino acids of transport proteins,
in particular of multidrug resistance proteins, thanks to
increasing intracellular ROS (10, 34). Multidrug resistance
arises primarily due to the up-regulation of proteins from the
adenosine triphosphate binding cassette transporter family.
Sensitivity to chemotherapy is strongly dependent on the
expression of multidrug-resistance related transporters (35).
HBO has been observed to inhibit multi drug-resistance-related
transporters therefore enhancing anticancer activity of
chemotherapy (9). Finally, TNF-α is implicated in the
processes of tumor growth, survival, differentiation, invasion,
metastasis, secretion of cytokines and pro-angiogenic factors.
HBO has been reported to inhibit TNF-α production in
ischemia reperfusion tissue injury (36, 37). HBO was also
reported to reduce interleukin-1 production of macrophage
(38). Since interleukin-1, in particular, is able to stimulate
metastasis and growth of the cell lines we used here, HBO
might enhance apoptosis by inhibiting its production (39). 
In summary, HBO-alone was found to have no effects on
apoptosis of pancreatic tumor cells in vitro. HBO did not
enhance gemcitabine-induced apoptosis of pancreatic tumor
cells when administered before or after chemotherapy. HBO
significantly enhanced gemcitabine-induced apoptosis of
pancreatic tumor cells when administered concomitantly with
chemotherapy. Our study suggests that the time window of
therapy is critical for effectively using HBO as adjuvant to
chemotherapy. 
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